La cadena de opciones muestra datos clave de las opciones de acciones de FOXO Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para FOXO Technologies..

FOXO Technologies (AMEX:FOXO) Bolsa, Cadena de Opciones

FOXO Technologies

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. The company's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life. The Company manages and classifies its business into two reportable business segments: Healthcare; and Labs and Life.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

WIIM

OKLO

Oklo shares are trading higher after Seaport Global upgraded the stock from Neutral to Buy and announced a $71 price target.

WBD stock has given up its prior gain. Warner Bros Discovery shares were trading higher. The company announced plans to separate the company into two publicly traded companies.

Citigroup analyst Christopher Danely maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and raises the price target from $55 to $68.

Price Target

Analyst Ratings

MCHP

Citigroup Maintains Buy on Microchip Technology, Raises Price Target to $68

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has quietly joined the ranks of <a href="https://www.benzinga.com/topic/s-p-500-index">the S&amp;P 500</a>'s biggest EPS disappointments in the first quarter.
According to <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_060625A.pdf">FactSet</a>, Tesla landed in the bottom 10 for Actual EPS Surprise %, with its first quarter earnings missing expectations by a stark 25.3% ― a notable spot of underperformance for the EV leader.
<h2 class="wp-block-heading">Tesla's EPS Shock: A Quarter To Forget</h2>
That 25% miss puts Tesla alongside companies like Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and First Solar Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) ― far from its usual club of beats.
The data paints a different portrait than the company's headline-grabbing innovations: Tesla is being lumped in with chicken-footed performers, not the industry disruptors.
Read Also: <a href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war">Tesla China Sales Surge In May As New Model Y Juniper Exported For The First Time Amid US-China Trade War</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="628" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png" alt="" class="wp-image-943497" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM-300x233.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Can TSLA Chart Hold The Line At ~$290?</h2>
Despite the miss, TSLA remains a tale of two markets. Over the past 12 months, it's up nearly 70%, but it has stumbled –22% year-to-date, trading near $293 ― well below both its eight-day and 20-day simple moving averages (SMAs), marking a crisp bearish signal . A deeper dip below this range could signal more technical pain.
Still, Tesla stock manages mixed signals. Its 50-day SMA at $292.32 sits just under current levels, hinting at a possible floor. Meanwhile, the MACD (moving average convergence/divergence) indicator remains positive and the RSI (relative strength index) floats around neutral, signaling technical balance but little conviction .
Why the miss? Production snags. Price cuts that carved into margins. Questions around demand ― especially as EV competition heats up and macro uncertainty lingers.
That said, Tesla's long-term narrative remains intact: its energy business is scaling, global expansion continues, and recurring software and FSD revenue could restore margin optimism.
<h2 class="wp-block-heading">What&#8217;s Next For TSLA Investors?</h2>
TSLA investors may want to keep an eye on:
<ul class="wp-block-list">
<li>Tesla&#8217;s second quarter guidance and any recalibration in price strategy.</li>
<li>The stock&#8217;s technical support and whether it holds around the $290–295 zone or gives way to deeper downside.</li>
<li>A shift in narrative &#8211; if Tesla leans back into margin talk and software recurring revenues, the stock could rebound despite short-term jitters.</li>
</ul>
The investors' dilemma is clear: Tesla may be among the S&amp;P's most disappointing EPS misses in the first quarter, but is that a signal of long-term trouble &#8211; or just a short-lived blip?
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45834012/tom-lee-dismisses-worries-over-tumbling-tsla-stock-amid-elon-musk-trump-feud-tesla-still-holds-all-of-its-advantages-so-we-arent-too-concerned">Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: &#8216;Tesla Still Holds All Of Its Advantages, So We Aren&#8217;t Too Concerned&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Technicals

Tech

FSLR

NCLH

TSLA

Tesla Among S&P's Big Losers: Q1 EPS Miss Puts TSLA In Bottom 10

Morgan Stanley analyst Annelies Vermeulen maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and raises the price target from $195 to $220.

FERG

Morgan Stanley Maintains Overweight on Ferguson Enterprises, Raises Price Target to $220

Metsera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera&#8217;s fully-biased monthly GLP-1 <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">receptor agonist candidate</a>, MET-097i.
In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45832929/metsera-announces-positive-phase-1-data-of-first-in-class-once-monthly-amylin-candidate-met-233i" rel="noreferrer noopener">with no safety signals</a>.
MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/03/44102235/why-did-metsera-stock-surge-15-on-the-worst-trading-day-of-2025-heres-what-has-happened-since-its-listing" rel="noreferrer noopener">Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here&#8217;s What Has Happened Since Its Listing</a>
Topline results from the Phase 1 trial include:
<ul class="wp-block-list">
<li>Dose-linear pharmacokinetics with an observed half-life of 19 days&nbsp;from dose to 50% of Cmax, supporting the potential for once-monthly dosing with simplified titration.</li>
<li>Body weight loss was dose-dependent, ranging from a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. 
<ul class="wp-block-list">
<li>In the trial&#8217;s single ascending dose (SAD) portion, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i.</li>
</ul>
</li>
<li>Gastrointestinal adverse events in the trial&#8217;s multiple ascending dose (MAD) portion were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid tolerance onset despite a three-fold exposure accumulation over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the trial&#8217;s SAD and the MAD portions.</li>
<li>To date, no severe or serious adverse events have been observed in the SAD or MAD portion of the trial.</li>
</ul>
Next Steps: Based on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i:
<ul class="wp-block-list">
<li>An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025.</li>
<li>Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to 12 weeks. Topline data are expected by year-end 2025 or early 2026.</li>
</ul>
The company also expects to report topline clinical data from its ultra-long-acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025.
The company anticipates that MET-034i will be the third peptide engineered with Metsera&#8217;s HALO platform to enter clinical testing.
MTSR Price Action: Metsera stock is up 13.24% at $31.13 at publication on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

MTSR

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Citigroup analyst Christopher Danely maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Neutral and raises the price target from $100 to $120.

Citigroup Maintains Neutral on Advanced Micro Devices, Raises Price Target to $120

B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and raises the price target from $48 to $54.

B of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $54

Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in <a href="https://www.benzinga.com/general/biotech">Facioscapulohumeral Muscular Dystrophy (FSHD)</a>.
FSHD is a genetically acquired disease that leads to progressive muscle weakness&nbsp;and severely decreased functional capacity.
The data will be presented at the 32nd Annual <a href="https://www.benzinga.com/pressreleases/25/06/n45832986/avidity-biosciences-announces-positive-topline-phase-12-fortitude-data-demonstrating-consistent-im">FSHD Society International Research Congress</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44361572/avidity-biosciences-touts-positive-data-from-early-stage-duchenne-muscular-dystrophy-study-data-fda-submission-expected-by-end-of-2025" target="_blank" rel="noreferrer noopener">Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025</a>
Del-brax is the first investigational therapy designed to treat the underlying cause of FSHD by directly targeting the disease-causing gene, double homeobox 4 (DUX4).
FSHD affects approximately 45,000 to 87,000 people in&nbsp;the United States&nbsp;and&nbsp;Europe.
Topline data from these cohorts for del-brax treated participants, compared to placebo, demonstrated:
<ul class="wp-block-list">
<li>Consistent improvement of functional mobility and muscle strength as measured by 10-meter Walk-Run test (10MWRT), Timed Up and Go (TUG), and quantitative muscle testing (QMT) as compared to placebo;</li>
<li>Consistent improvement in multiple measures of quality of life as measured by patient-reported outcomes and compared to placebo;</li>
<li>Rapid and significant reductions in levels of KHDC1L and creatine kinase, a biomarker of muscle damage.</li>
<li>Favorable long-term safety and tolerability with most adverse events (AEs) mild or moderate, with no related serious or severe adverse events and no discontinuations.</li>
</ul>
Topline data from the ongoing, fully enrolled del-brax Phase 1/2 FORTITUDE biomarker cohort are anticipated in Q2 2026.
The primary endpoint of the FORTITUDE biomarker cohort is reduction of KHDC1L, a novel DUX4-regulated circulating biomarker.
Avidity also announced that the accelerated approval regulatory pathway in the U.S. is open for del-brax and that the company has initiated the global, confirmatory Phase 3 FORWARD study in FSHD.
In a recent research note, Chardan Capital analyst Keay Nakae set a 12-month price target of $75 per share for Avidity Biosciences. The valuation stems from a Net Present Value (NPV) model of the company&#8217;s projected revenues from its RNA therapeutics pipeline, forecasted out to the year 2034.
Chardan maintained its Buy rating and increased its price forecast from $65 to $75. According to Nakae&#8217;s analysis, the valuation incorporates specific &#8220;probability of success&#8221; rates for each of Avidity&#8217;s drug candidates to account for clinical and regulatory risks.
His model assigns a 60% chance of success for the company&#8217;s FSHD candidate, 50% for its DM1 and DMD exon 44 candidates, and lower probabilities for other assets. The analyst applied a 14% Weighted Average Cost of Capital (WACC) as the discount rate to reflect the high-risk profile of the development-stage company.
Nakae also highlighted several significant risks that could impede Avidity from reaching the $75 price target. He noted that the company, which currently has no revenue-generating products, will likely require additional financing, potentially leading to shareholder dilution.
The analyst also pointed to the risks of intellectual property challenges, the critical nature of upcoming clinical trial outcomes, and the intense competition from larger, better-resourced companies in the biotechnology sector.
Price Action: RNA stock is trading lower by 11.6% to $32.03 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45797348/early-wins-regenxbios-gene-therapy-helps-duchenne-patients-walk-stronger-longer" target="_blank" rel="noreferrer noopener">Early Wins: RegenXBio&#8217;s Gene Therapy Helps Duchenne Patients Walk Stronger, Longer</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $201 to $216.

ASND

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $216

<a href="https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/" title="https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/">https://www.apple.com/newsroom/2025/06/macos-tahoe-26-makes-the-mac-more-capable-productive-and-intelligent-than-ever/</a>

Events

AAPL

Apple Introduces MacOS Tahoe Which Includes Many Features In iOS; Enhancing The Calling Experience By Bringing The Phone App To Mac

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are trading higher. Stocks may be gaining as traders await details about the United States and China trade talks.

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.89, a high estimate of $12.00, and a low estimate of $8.00. A 12.32% drop is evident in the current average compared to the previous average price target of $11.28. 
<img src="https://www.benzinga.com/files/images/story/2025/1749492062_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Arhaus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Arhaus. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arhaus compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Arhaus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Arhaus's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARHS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Arhaus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Arhaus: A Closer Look</h2>
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
<h3>Arhaus's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Arhaus showcased positive performance, achieving a revenue growth rate of 5.49% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Arhaus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Arhaus's ROE stands out, surpassing industry averages. With an impressive ROE of 1.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Arhaus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Arhaus's debt-to-equity ratio stands notably higher than the industry average, reaching 1.5. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARHS

Where Arhaus Stands With Analysts

Citigroup analyst Christopher Danely maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $110 to $130.

Citigroup Maintains Buy on Micron Technology, Raises Price Target to $130

Mizuho analyst David Belinger maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $105 to $115.

Mizuho Maintains Outperform on Walmart, Raises Price Target to $115

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $121.94, a high estimate of $146.00, and a low estimate of $99.00. This current average reflects an increase of 0.52% from the previous average price target of $121.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1749492052_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Emerson Electric among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$112.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$133.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$133.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$104.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$119.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$99.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$132.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Emerson Electric. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emerson Electric compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Emerson Electric's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Emerson Electric's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Emerson Electric analyst ratings.</a>
<h2>About Emerson Electric</h2>
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
<h3>Emerson Electric: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Emerson Electric displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.28%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Emerson Electric's ROE excels beyond industry benchmarks, reaching 2.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Emerson Electric's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.77, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Emerson Electric Through 17 Analysts

Investors with a lot of money to spend have taken a bullish stance on HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HCA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for HCA Healthcare.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $808,125, and 2 are calls, for a total amount of $57,170.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $325.0 to $385.0 for HCA Healthcare over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of HCA Healthcare stands at 444.86, with a total volume reaching 2,062.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in HCA Healthcare, situated within the strike price corridor from $325.0 to $385.0, throughout the last 30 days.
<h3>HCA Healthcare Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749492044_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$24.9</td>
<td>$22.6</td>
<td>$24.1</td>
<td>$385.00</td>
<td>$101.2K</td>
<td align="right">203</td>
<td align="right">92</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$20.2</td>
<td>$19.2</td>
<td>$20.2</td>
<td>$380.00</td>
<td>$101.0K</td>
<td align="right">189</td>
<td align="right">52</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.3</td>
<td>$11.0</td>
<td>$11.1</td>
<td>$365.00</td>
<td>$83.6K</td>
<td align="right">351</td>
<td align="right">163</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$23.6</td>
<td>$21.4</td>
<td>$22.3</td>
<td>$385.00</td>
<td>$82.5K</td>
<td align="right">203</td>
<td align="right">137</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.6</td>
<td>$9.1</td>
<td>$9.2</td>
<td>$350.00</td>
<td>$67.0K</td>
<td align="right">216</td>
<td align="right">76</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
After a thorough review of the options trading surrounding HCA Healthcare, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of HCA Healthcare</h3>
<ul>
<li>With a volume of 1,254,903, the price of HCA is down -3.2% at $372.06. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About HCA Healthcare</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $403.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on HCA Healthcare, which currently sits at a price target of $410. 
&#x2A; An analyst from Wells Fargo upgraded its action to Equal-Weight with a price target of $385. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on HCA Healthcare, which currently sits at a price target of $416. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

HCA Healthcare Options Trading: A Deep Dive into Market Sentiment

Ratings for Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Waste Management and provided 12-month price targets. The average target is $255.56, accompanied by a high estimate of $277.00 and a low estimate of $229.00. Witnessing a positive shift, the current average has risen by 8.63% from the previous average price target of $235.25.
<img src="https://www.benzinga.com/files/images/story/2025/1749492043_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Waste Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Wertheimer</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$277.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Bryan Burgmeier</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$229.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Wesley Brooks</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Konark Gupta</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$260.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waste Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Waste Management compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Waste Management's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Waste Management's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waste Management analyst ratings.</a>
<h2>Unveiling the Story Behind Waste Management</h2>
WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
<h3>A Deep Dive into Waste Management's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Waste Management's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.65% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Waste Management's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waste Management's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waste Management's ROA stands out, surpassing industry averages. With an impressive ROA of 1.43%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Waste Management's debt-to-equity ratio surpasses industry norms, standing at 2.76. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Waste Management Stands With Analysts

Whales with a lot of money to spend have taken a noticeably bearish stance on GE Vernova.
Looking at options history for GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) we detected 30 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 43% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $1,001,854 and 20, calls, for a total amount of $1,457,567.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $600.0 for GE Vernova, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for GE Vernova's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Vernova's whale activity within a strike price range from $200.0 to $600.0 in the last 30 days. 
<h3>GE Vernova 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749492039_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$99.4</td>
<td>$98.1</td>
<td>$99.3</td>
<td>$540.00</td>
<td>$327.6K</td>
<td align="right">14</td>
<td align="right">33</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$14.9</td>
<td>$13.4</td>
<td>$13.65</td>
<td>$520.00</td>
<td>$316.4K</td>
<td align="right">689</td>
<td align="right">266</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$20.5</td>
<td>$19.7</td>
<td>$20.0</td>
<td>$480.00</td>
<td>$170.0K</td>
<td align="right">48</td>
<td align="right">85</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$490.00</td>
<td>$159.5K</td>
<td align="right">346</td>
<td align="right">318</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$99.5</td>
<td>$98.1</td>
<td>$99.0</td>
<td>$540.00</td>
<td>$158.4K</td>
<td align="right">14</td>
<td align="right">131</td>
</tr>
</tbody>
</table>

<h3>About GE Vernova</h3>
GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.
Following our analysis of the options activities associated with GE Vernova, we pivot to a closer look at the company's own performance.
<h3>Where Is GE Vernova Standing Right Now?</h3>
<ul>
<li>With a volume of 1,275,928, the price of GEV is down -0.63% at $481.93. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for GE Vernova</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $499.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on GE Vernova, which currently sits at a price target of $500. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on GE Vernova, which currently sits at a price target of $460. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for GE Vernova, targeting a price of $522. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on GE Vernova, maintaining a target price of $499. 
&#x2A; Reflecting concerns, an analyst from Jefferies lowers its rating to Hold with a new price target of $517.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for GE Vernova, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

GE Vernova Options Trading: A Deep Dive into Market Sentiment

4 analysts have shared their evaluations of Concrete Pumping Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $7.38, along with a high estimate of $9.00 and a low estimate of $6.00. A decline of 7.75% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749492034_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Concrete Pumping Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$6.50</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.50</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Concrete Pumping Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Concrete Pumping Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Concrete Pumping Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Concrete Pumping Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBCP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Concrete Pumping Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Concrete Pumping Holdings</h2>
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.
<h3>Concrete Pumping Holdings: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Concrete Pumping Holdings's revenue growth over 3M faced difficulties. As of 30 April, 2025, the company experienced a decline of approximately -12.24%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -0.46%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.16%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.69, Concrete Pumping Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBCP

Deep Dive Into Concrete Pumping Holdings Stock: Analyst Perspectives (4 Ratings)

Press Releases

FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

FOXO TECHNOLOGIES, INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR TWO ASSISTED-LIVING FACILITIES IN FLORIDA FOR A TOTAL CONSIDERATION OF $60 MILLION

Comments

FOXO Technologies

FOXO Technologies (FOXO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL